Yazar "Koksaldi-Motor, Vicdan" seçeneğine göre listele

Listeleniyor 1 - 3 / 3
  • [ N/A ]
    Öğe
    Investigation of vitamin D levels in patients with inactive hepatitis B virus carrier
    (Acta Medica Mediterranea, 2014) Motor, Sedat; Koksaldi-Motor, Vicdan; Dokuyucu, Recep; Ustun, Ihsan; Evirgen, Omer; Yilmaz, Nigar; Onlen, Yusuf
    Objective: The purpose of the present study was to investigate vitamin D levels in inactive hepatitis B virus carriers. Materials and methods: A total of 81 patients with inactive hepatitis B virus carrier state were enrolled at the study. Serum calcium (Ca++), phosphorus (PO4), total protein, albumin, parathormone (PTH) and 25-hydroxy vitamin D (25OHD) were determined. Serum vitamin D concentration was classified as lacking when it was less than 50 nmol/l (20 ng/ml), insufficient when it was 52.5-72.5 nmol/l (21-29 ng/ml), and sufficient when it was more than 75 nmol/l (30-100 ng/ml). Results: The mean 25OHD level was found to be 131.7±50.0 nmol/l. Deficiency and insufficiency was seen in one (1.2 %) and nine (11.1 %) inactive hepatitis B virus carriers, respectively. All the patients have normal serum PTH and albumin levels. Total Ca++ and PO4 were low in ten and eight patients, respectively (p<0.05). Conclusion: Vitamin D may cause the stimulation of antiviral immune response and a preventive effect on necroinflammation and liver fibrosis. Therefore, it may affect course of HBV infection. The new studies with larger sample are needed to research the role of vitamin D in the course of chronic HBV infection, liver failure, cirrhosis, and hepatocellular carcinoma.
  • Küçük Resim
    Öğe
    INVESTIGATION OF VITAMIN D LEVELS IN PATIENTS WITH INACTIVE HEPATITIS B VIRUS CARRIER
    (Carbone Editore, 2014) Motor, Sedat; Koksaldi-Motor, Vicdan; Dokuyucu, Recep; Ustun, Ihsan; Evirgen, Omer; Yilmaz, Nigar; Onlen, Yusuf
    Objective: The purpose of the present study was to investigate vitamin D levels in inactive hepatitis B virus carriers. Materials and methods: A total of 81 patients with inactive hepatitis B virus carrier state were enrolled at the study. Serum calcium (Ca++), phosphorus (PO4), total protein, albumin, parathormone (PTH) and 25-hydroxy vitamin D (25OHD) were determined. Serum vitamin D concentration was classified as lacking when it was less than 50 nmolll (20 ng/ml), insufficient when it was 52.5-72.5 nmol/l (21-29 ng/ml), and sufficient when it was more than 75 nmol/l (30-100 ng/ml). Results: The mean 25OHD level was found to be 131.7 +/- 50.0 nmol/l. Deficiency and insufficiency was seen in one (1.2 %) and nine (11.1 %) inactive hepatitis B virus carriers, respectively. All the patients have normal serum PTH and albumin levels. Total Ca++ and PO4 were low in ten and eight patients, respectively (p<0.05). Conclusion: Vitamin D may cause the stimulation of antiviral immune response and a preventive effect on necroinflammation and liver fibrosis. Therefore, it may affect course of HBV infection. The new studies with larger sample are needed to research the role of vitamin D in the course of chronic HBV infection, liver failure, cirrhosis, and hepatocellular carcinoma.
  • Küçük Resim
    Öğe
    Lamivudine Experience in Acute Hepatitis B Developing in a Patient Under Chemotherapy
    (Aves, 2014) Bal, Tayibe; Onlen, Yusuf; Isitemiz, Feride; Koksaldi-Motor, Vicdan; Evirgen, Omer; Kokoglu, Omer Faruk; Ocak, Sabahattin
    Acute hepatitis B (AHB) results 90% in spontaneous healing and often does not require antiviral therapy. It may rarely result in severe liver damage as fulminant hepatitis. The possibility of fulminant hepatitis is high in immunosuppressed patients than in immunocompetent patients. Although the exact cause is unexplained, immunosuppression associated with chemotherapy may increase the possibility of fulminant hepatitis by increasing hepatitis B virus replication in immunosuppressed patients. According to this hypothesis, in immunosuppressed patients with AHB, maintaining viral load suppression with lamivudine therapy may cause less host response and may be effective in preventing risk of fulminant hepatitis. A case in which AHB developed while receiving maintenance chemotherapy for haematological malignancy is presented. Based on similar cases in the literature, the patient was treated with lamivudine and maintenance chemotherapy was continued. In the fourth week of treatment, transaminase levels were normal and anti-HBs was positive. In immunocompromised patients in whom AHB develops, many questions such as the effectiveness of lamivudine treatment, duration of treatment, whether or not to suspend the chemotherapy and when to continue the chemotherapy are still unanswered. Lamivudine experience in this case is reported because there is no guide for this subject in the literature except few case reports.